Adherence and completion to multidose vaccine schedules for hepatitis A, B, and A-B are low, thereby rendering vaccination ineffective.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
From 2007 to 2015, the majority of initial hepatitis A, B, and A/B vaccinations were administered by primary care providers.
Of the 2500 cases of hepatitis A infection reported between January 2017 and April 2018, 68% were among persons who reported drug use (injection and non-injection), homelessness, or both.
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
Future studies might focus on the use of electronic medical record warning systems or other prompts to improve diagnostic test use in at-risk individuals.
Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
The Work Group who authored the new recommendations was made up of professionals from academic medicine, federal and state public health agencies, and medical societies.
The 3-part plan to halt the outbreak of hepatitis A focuses on immunization, sanitation and education with most of the efforts focused on the homeless population who are the most at-risk population.
The American College of Gastroenterology has released recommendations of preferred approaches for diagnosing and evaluating patients with abnormal liver test results.
A 50-year-old man presents to the emergency department with abdominal pain, nausea, jaundice, and dark urine.
A patient's positive hepatitis B results were overlooked for 7 years.
A greater understanding of the healthcare issues specific to the lesbian, gay, bisexual, and transgender community may improve the quality of care.
More than half of Americans polled were unsure or unaware of the existence of a hepatitis B vaccine.
No reports of adverse events with intradermal recombinant HBsAg-based vaccine.
Nearly all pregnant women with hepatitis B virus (HBV) taking telbivudine had undetectable levels of HBV DNA in cord blood.
The combination of entecavir and birinapant eradicated the hepatitis B virus in preclinical trials.
Strengthening current hepatitis B virus prevention and treatment efforts can reduce related mortality.
Immunosuppressive agents do not increase the risk of HCV flares in anti-HCV-positive lupus patients.
Overall survival was significantly improved for patients treated with nucleoside analogues (NAs) versus those who received no NAs.
Daclatasvir plus sofosbuvir demonstrated a sustained virological response in 98% of patients with genotype 1 hepatitis C infection.
Projects funded by the grant will aid public health efforts to reduce the burden of viral hepatitis in the United States.
A community-based organization focused on eliminating hepatitis-related health disparities issued a report detailing improvements that can be made for better hepatitis care.
The risk-benefit profile of more widespread hepatitis C screening is not sufficiently understood, researchers suggest.
Researchers have eliminated hepatitis C as the cause of impaired mental function in HIV patients.
To prevent reactivation, appropriate antiviral therapy should be given to patients who are found to be HBsAg positive.
Combination simeprevir and sofosbuvir has been approved by the FDA for treatment of chronic genotype 1 hepatitis C.
Fatty liver disease and other topics gained traction at the AASLD Annual Meeting as HCV therapy research plateaus.